Protein PowdersGuide6 min
Ozempic Face and Hair Shedding: What the Labels Actually Say
Facial volume loss is not a listed side effect of any of these drugs. Hair loss is on two labels. Here is exactly what each one reports, and what it means.
TL;DR
Key takeaways
- “Ozempic face” is a nickname, not a diagnosis. None of the current FDA labels for semaglutide, tirzepatide or liraglutide lists a facial-volume adverse reaction. Facial fat is fat; it goes when body fat goes.
- Hair loss is in the Wegovy and Zepbound trial tables — Wegovy 3% at 2.4 mg and 6% at 7.2 mg against 1% on placebo; Zepbound 4 to 5% across doses against 1% on placebo.
- For Ozempic, oral semaglutide, Mounjaro, Saxenda and Victoza, alopecia appears only under postmarketing experience — which each label says cannot reliably establish frequency or causation.
- Zepbound's own label says the hair-loss reactions were associated with weight reduction, and reports them more often in female than male patients.
- The pattern described is telogen effluvium: triggered by things including crash dieting and low protein intake, starting about three months after the trigger, and described as benign and reversible.
Pick by your situation
| If your situation is… | Pick | Why |
|---|---|---|
| Your face has changed and it is bothering you | A conversation, not a product | No FDA label lists a facial-volume reaction, and nothing sold as a fix for it has a claim we would repeat. |
| Shedding started and you want to know if it is the drug | Check which label your drug has | Wegovy and Zepbound report hair loss in trial tables; the others carry only a postmarketing listing, which establishes neither frequency nor cause. |
| You are eating far less than you used to | Protein adequacy first | Low protein intake and crash dieting are both on the standard telogen-effluvium trigger list. |
| The weight is coming off very fast | Ask about pace at your next visit | Zepbound's label ties its hair-loss reactions to weight reduction, and pace is the one variable only a prescriber can adjust. |
| You are considering a hair or skin supplement | Tell your clinician what you are taking first | NIH ODS finds little evidence for biotin claims, and biotin can skew thyroid lab tests that are used to look for another cause of shedding. |
Each pick is one of the products compared below — a shortcut by situation, not a separate recommendation.
Two of the most-searched worries on this medication have almost nothing to do with the medication's mechanism and almost everything to do with how fast the weight is coming off. That is not a dismissal — hair coming out in the shower is genuinely distressing. It is a reframe, and it changes what you can usefully do about it.
Here is what the FDA labels say, what "Ozempic face" is a nickname for, and what is honestly known about the shedding.
Worth raising at your next visitFrom this guide
Worth raising at your next visit: the lever here is the pace of your weight loss and the adequacy of your intake, and only your prescriber can adjust the first one. Hair shedding also has causes that have nothing to do with weight — thyroid changes and iron deficiency among them — so it is a reason to ask rather than a reason to self-diagnose. Bring the timeline: when the shedding started, and what the preceding three months looked like.
"Ozempic face" is not a side effect
It is a media coinage, not a clinical term, and it describes facial volume loss that comes with losing a lot of weight relatively quickly — by any means. Facial fat is fat. When body fat falls, some of it comes from the face, and faces read thinness as ageing in a way that waistlines do not.
We read the current FDA prescribing information for (Ozempic, Wegovy, the oral tablets), (Mounjaro, Zepbound) and (Saxenda, Victoza). None of them lists a facial-volume adverse reaction of any kind. That is a real finding rather than an absence of effort: the labels are detailed enough to enumerate eructation and dysesthesia, and facial volume simply is not in them.
We sell nothing for this and claim nothing about it.
What the labels actually say about hair
Hair does appear on these labels — and where it appears differs by product in a way that is worth knowing.
| Label | Where hair appears | What it reports |
|---|---|---|
| Wegovy (semaglutide) | Adverse reactions from clinical trials | Hair loss in 3% on 2.4 mg weekly versus 1% on placebo; in the 7.2 mg trials, 6% versus 3% on 2.4 mg and 1% on placebo |
| Zepbound (tirzepatide) | Adverse reactions from clinical trials, plus its own subsection | Hair loss in 5%, 4% and 5% at 5, 10 and 15 mg versus 1% on placebo |
| Ozempic, oral semaglutide, Mounjaro, Saxenda, Victoza | Postmarketing experience only | Alopecia, listed under skin and subcutaneous tissue disorders |
Two details carry most of the meaning.
First, Zepbound's label draws the connection itself. Its hair-loss subsection states that hair-loss adverse reactions in treated patients were associated with weight reduction, and that hair loss was reported more frequently in female than male patients — 7.1 percent versus 0.5 percent in the treatment groups, against 1.3 percent and 0 percent on placebo. No treated patient discontinued because of it. A label saying an effect tracks the weight reduction is a label pointing at the same mechanism the dermatology literature describes.
Second, a postmarketing listing is a weaker statement than a trial table. Every label carrying one says so in its own words: those reactions are reported voluntarily from a population of uncertain size, so it is not always possible to reliably estimate frequency or establish a causal relationship to the drug. "Alopecia is in the Ozempic label" is true, and it means less than it sounds like.
Telogen effluvium: the thing being described
The pattern people report — diffuse shedding, no bald patches, hair coming out all over rather than in one place — matches telogen effluvium, which is the excessive shedding of resting hair after a metabolic stress, a hormonal change or a medication.
The clinical picture explains the confusion almost entirely:
- The trigger list includes crash dieting and low protein intake, alongside major surgery, severe infection, postpartum hormonal change, thyroid problems and iron deficiency.
- The causative event typically occurred about three months before the shedding starts, though the range runs from one to six months. By the time you notice, the stretch that caused it is over.
- Acute telogen effluvium lasts less than six months by definition, and often much less.
- It is described as benign and spontaneously reversible, and the standard clinical advice includes reassurance about the likelihood of recovering hair density with time and nutritional support.
Three months of lag is why this feels random and why it so often arrives after the fastest stretch of loss rather than during it. It is also why the useful timeline to bring to an appointment is the previous three months, not the previous three weeks.
What may help — and who decides
Everything below is framed the way we frame everything: these support intake and comfort. Nothing here treats or reverses shedding.
Protein adequacy. Low protein intake is on the trigger list, and it is the piece a small appetite makes hardest. The 2026 Nutrients review of nutrition-first support during therapy puts total protein for adults in active weight reduction at approximately 1.2 to 1.6 g per kg per day, adjusted for age, renal function and comorbidities — with the explicit caveat that anyone with chronic kidney disease or a protein restriction should not apply a higher target without individual assessment. There is no universal number and we do not publish one. The practical version for a small appetite is protein-first eating on a GLP-1; the protein powders shelf covers the eating occasions where food is not happening.
Pace. The same review notes that guidance commonly manages the rate of loss rather than maximising it. That is not a decision to make alone. Discuss the pace with your prescriber.
What we do not sell, and do not claim
We do not sell collagen, biotin or anything else marketed at hair, and we are not going to start.
On biotin specifically, NIH's Office of Dietary Supplements is direct: supplements containing biotin are often promoted to improve hair, skin and nail health, but there is little scientific evidence to support these claims, and more research is needed before biotin can be recommended for any of them. Biotin deficiency is itself very rare in the United States. There is also a practical catch worth knowing — biotin above recommended amounts can cause false results in some lab tests, including thyroid hormone measurements. Given that thyroid problems are on the telogen-effluvium trigger list, a supplement that can distort the test used to check for one is a poor first move. Tell your clinician what you are taking.
Device-based options aimed at skin and hair exist and are a whole separate category of product. We do not cover them, and this site has no view on them.
The honest summary
Facial volume loss is a consequence of losing fat, not a drug reaction. Hair shedding is on two of these labels as a trial-reported reaction, on several more as a postmarketing report, and one manufacturer's own label ties it to the weight reduction rather than to the molecule. The shedding described is a benign and self-limiting pattern with a three-month lag built into it.
The two things worth acting on are the two you can actually influence: eat enough protein, and talk to your prescriber about pace. Everything else marketed at this is selling you the wait.
Your next step
The one thing here you can act on is protein. This is where to get it.
Frequently asked
The questions that keep coming up
Is Ozempic face a side effect of the medication?
Not as the labels describe it. We read the current FDA prescribing information for semaglutide, tirzepatide and liraglutide products, and none lists a facial-volume adverse reaction. What the term describes is facial fat loss that accompanies losing a substantial amount of weight, by any method. If your face has changed and it bothers you, that is worth raising with a clinician — but it is a consequence of the weight loss rather than a reaction to the drug.
Does Ozempic cause hair loss?
Alopecia appears in the Ozempic label only under postmarketing experience, in the skin and subcutaneous tissue category. That section of every label carries the same caveat: the reports arrive voluntarily from a population of uncertain size, so frequency cannot be reliably estimated and a causal relationship to the drug cannot be established. Hair loss appears more concretely in the Wegovy and Zepbound clinical-trial tables.
How much hair loss did the trials actually report?
In the Wegovy trials, hair loss was reported by 3 percent of patients on 2.4 mg weekly versus 1 percent on placebo; in the 7.2 mg trials it was 6 percent on 7.2 mg, 3 percent on 2.4 mg and 1 percent on placebo. In the Zepbound trials it was 5, 4 and 5 percent at 5, 10 and 15 mg versus 1 percent on placebo. Zepbound's label adds that the reactions were associated with weight reduction and were more frequent in female patients, 7.1 percent versus 0.5 percent.
When does the shedding usually start, and does it stop?
In telogen effluvium the causative event typically occurred about three months before the shedding begins, with a range of roughly one to six months. Acute telogen effluvium is defined as lasting less than six months and is often shorter. It is described in the clinical literature as benign and spontaneously reversible, with recovery of hair density expected over time alongside nutritional support. Shedding that does not follow that pattern is a reason to see a clinician.
Will collagen or biotin help?
We do not sell them and we make no claim for them. NIH's Office of Dietary Supplements states that supplements containing biotin are often promoted for hair, skin and nail health but that there is little scientific evidence to support these claims, and that more research is needed before biotin can be recommended for any of them. It also warns that biotin above recommended amounts can cause false results in some lab tests, including thyroid hormone tests, which matters because thyroid problems are themselves on the shedding trigger list.
What should I actually ask my prescriber?
Bring a timeline: when the shedding started and what the previous three months of weight loss looked like. Ask whether the pace of loss can be adjusted, and whether anything else on the standard trigger list applies to you, since thyroid changes and iron deficiency also cause this pattern and have nothing to do with the medication. Ask what protein target they want you on. Do not change or stop a medication on your own.
Sources & further reading
We research from primary and authoritative sources. Where our guidance rests on a fact, here's where it comes from.
- DailyMed — WEGOVY (semaglutide) injection, prescribing information — Section 6.1. Table 3 (2.4 mg once weekly, N=2,116 versus placebo N=1,261): Hair Loss 3% versus 1%. Table 4 (7.2 mg N=1,311, 2.4 mg N=304, placebo N=303): Hair loss 6%, 3%, 1%. Hair loss also appears in the label's Highlights list of most common adverse reactions.
- DailyMed — ZEPBOUND (tirzepatide) injection, prescribing information — Section 6.1. Table 1: Hair Loss 5%, 4% and 5% at 5, 10 and 15 mg versus 1% on placebo (N=958). The label's own Hair Loss subsection states the hair loss adverse reactions were associated with weight reduction, reports 7.1% of female versus 0.5% of male treated patients against 1.3% and 0% on placebo, and notes no treated patient discontinued because of it.
- DailyMed — OZEMPIC (semaglutide) injection, prescribing information — Section 6.2 Postmarketing Experience lists alopecia under Skin and Subcutaneous Tissue, and opens with the standard caveat that these reactions are reported voluntarily from a population of uncertain size, so it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure. No facial-volume adverse reaction appears anywhere in the label.
- DailyMed — MOUNJARO (tirzepatide) injection, prescribing information — Alopecia appears only in the postmarketing experience section under Skin and Subcutaneous Tissue, with the same frequency and causality caveat. Checked alongside the oral semaglutide label (setid 27f15fac), SAXENDA (3946d389) and VICTOZA (5a9ef4ea), each of which lists alopecia in postmarketing experience only.
- Telogen Effluvium — StatPearls, NCBI Bookshelf (National Library of Medicine) — Excessive shedding of resting hair after metabolic stress, hormonal change or medication. Trigger list includes crash dieting, low protein intake, hypothyroidism and iron deficiency. A causative event is typically found about 3 months before onset, range 1 to 6 months; acute telogen effluvium lasts under 6 months by definition; the condition is described as benign and spontaneously reversible, with reassurance about recovery of hair density with time and nutritional support.
- NIH Office of Dietary Supplements — Biotin, consumer fact sheet — States that supplements containing biotin are often promoted to improve hair, skin and nail health but there is little scientific evidence to support these claims, and more research is needed before biotin can be recommended for any of these conditions. Also that biotin deficiency is very rare in the United States, and that biotin above recommended amounts may cause false results in some lab tests including thyroid hormone tests.
- Zambrano-Villacres et al., Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity, Nutrients (2026), PMC13258902 — Source of the protein range of approximately 1.2 to 1.6 g/kg/day adjusted for age, renal function and comorbidities, the statement that higher targets should not be applied in chronic kidney disease without individual clinical and dietetic assessment, and the point that obesity guidance commonly manages the rate of weight loss rather than maximising it.
LeanFed is not medical advice and is not a substitute for your prescriber, pharmacist or dietitian. We do not test products hands-on — we compare labels, specifications and owner reviews. Prices and LeanScores reflect our most recent research and refresh on a cycle; confirm the current price and read the product's own label before buying. We may earn a commission from affiliate retailers — it never changes our recommendations. See how we score.